EGFR and non-small cell lung carcinoma: Our data suggest a differential effect of erlotinib on destabilizing various EGFR mutants which, along with differential ATP affinity and drug binding of EGFR mutants, is responsible for differential therapeutic outcomes observed in subsets of NSCLC patients.